Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-813160

Generic Name: BMS-813160

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₄₀N_₈O_₂

CAS Number: 1286279-29-5

Unique Ingredient Identifier: 83U7957287

Overview

BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Phase 2

Active, not recruiting

Posted: 2019/10/10

Sponsor:Icahn School of Medi...

ID:NCT04123379

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

Completed

Posted: 2018/04/12

Sponsor:Washington Universit...

ID:NCT03496662

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Posted: 2017/06/14

Sponsor:Bristol-Myers Squibb

ID:NCT03184870

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

Phase 2

Completed

Posted: 2016/12/19

Sponsor:Bristol-Myers Squibb

ID:NCT02996110

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Phase 2

Terminated

Posted: 2012/12/19

Sponsor:Bristol-Myers Squibb

ID:NCT01752985

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy